RFL vs. CODX, CTCX, NAII, QNCX, ICCC, PXDT, VYNE, SABS, ESLA, and LFWD
Should you be buying Rafael stock or one of its competitors? The main competitors of Rafael include Co-Diagnostics (CODX), Carmell (CTCX), Natural Alternatives International (NAII), Quince Therapeutics (QNCX), ImmuCell (ICCC), Pixie Dust Technologies (PXDT), VYNE Therapeutics (VYNE), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), and ReWalk Robotics (LFWD). These companies are all part of the "medical" sector.
Rafael (NYSE:RFL) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
Rafael has a net margin of 776.36% compared to Co-Diagnostics' net margin of -582.36%. Rafael's return on equity of -4.31% beat Co-Diagnostics' return on equity.
In the previous week, Rafael had 11 more articles in the media than Co-Diagnostics. MarketBeat recorded 26 mentions for Rafael and 15 mentions for Co-Diagnostics. Rafael's average media sentiment score of 0.08 beat Co-Diagnostics' score of -0.01 indicating that Rafael is being referred to more favorably in the media.
11.3% of Rafael shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 9.7% of Rafael shares are held by company insiders. Comparatively, 2.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Co-Diagnostics has a consensus target price of $2.00, indicating a potential upside of 75.44%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Rafael.
Co-Diagnostics received 273 more outperform votes than Rafael when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 0.00% of users gave Rafael an outperform vote.
Rafael has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, meaning that its share price is 165% less volatile than the S&P 500.
Rafael has higher earnings, but lower revenue than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.
Summary
Rafael beats Co-Diagnostics on 11 of the 16 factors compared between the two stocks.
Get Rafael News Delivered to You Automatically
Sign up to receive the latest news and ratings for RFL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
